Both Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) and Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) are Biotechnology companies, competing one another. We will compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals Inc. N/A 0.00 10.67M -0.23 0.00 Alder Biopharmaceuticals Inc. N/A 1047.53 304.82M -4.49 0.00 Table 1 highlights Ampio Pharmaceuticals Inc. and Alder Biopharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 shows us the return on equity, return on assets and net margins of both companies.
Risk and Volatility
A 0.13 beta indicates that Ampio Pharmaceuticals Inc. is 87.00% less volatile compared to S&P 500. Competitively, Alder Biopharmaceuticals Inc.’s beta is 2.73 which is 173.00% more volatile than S&P 500.
In next table is given Ampio Pharmaceuticals Inc. and Alder Biopharmaceuticals Inc.’s ratings and recommendations.
Meanwhile, Alder Biopharmaceuticals Inc.’s average price target is $18, while its potential upside is 25.44%.
Institutional & Insider Ownership
Institutional investors owned 23.2% of Ampio Pharmaceuticals Inc. shares and 0% of Alder Biopharmaceuticals Inc. shares. Ampio Pharmaceuticals Inc.’s share owned by insiders are 7%. Insiders Comparatively, owned 0.4% of Alder Biopharmaceuticals Inc. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Ampio Pharmaceuticals Inc. -16.28% -0.37% 1.43% -71.67% -66.29% -86.91% Alder Biopharmaceuticals Inc. -14.8% -21.86% -35.59% -30.7% 4.11% -0.44% For the past year Ampio Pharmaceuticals Inc. was more bearish than Alder Biopharmaceuticals Inc.
On 5 of the 8 factors Alder Biopharmaceuticals Inc. beats Ampio Pharmaceuticals Inc.
Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis. In addition, the company has preclinical programs in the discovery phase for various indications. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Click here to view original web page at Reviewing Ampio Pharmaceuticals Inc. (AMPE)’s and Alder Biopharmaceuticals Inc. (NASDAQ:ALDR)’s results